Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNZ-2591 in Pitt Hopkins Syndrome
NCT05025332Phase 2Completed
- Sponsor
- Neuren Pharmaceuticals Limited
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of NNZ-2591 in Pitt-Hopkins syndrome (PTHS), sponsored by Neuren Pharmaceuticals Limited. Started Oct 2022; status: completed.
02
Drugs
NNZ-2591
03
Conditions
Pitt-Hopkins syndrome (PTHS)
Beyond the preview
Go deeper on NCT05025332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025332.